Oak Family Advisors LLC Invests $7.87 Million in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Oak Family Advisors LLC bought a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 64,631 shares of the medical equipment provider's stock, valued at approximately $7,866,000. Zimmer Biomet comprises 3.3% of Oak Family Advisors LLC's portfolio, making the stock its 4th largest holding.

Several other large investors have also added to or reduced their stakes in ZBH. Clear Street Markets LLC bought a new stake in Zimmer Biomet during the fourth quarter worth $27,000. Lazard Asset Management LLC grew its holdings in Zimmer Biomet by 70.5% during the third quarter. Lazard Asset Management LLC now owns 283 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 117 shares during the period. Dark Forest Capital Management LP purchased a new stake in Zimmer Biomet in the first quarter worth $35,000. Activest Wealth Management raised its stake in shares of Zimmer Biomet by 410.4% in the fourth quarter. Activest Wealth Management now owns 342 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 275 shares during the period. Finally, Peoples Bank KS purchased a new position in shares of Zimmer Biomet during the 3rd quarter valued at $48,000. Institutional investors own 88.89% of the company's stock.

Insiders Place Their Bets

In other news, VP Chad F. Phipps sold 26,156 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the transaction, the vice president now owns 44,145 shares in the company, valued at approximately $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 0.70% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ZBH shares. Canaccord Genuity Group restated a "hold" rating and issued a $130.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 23rd. JPMorgan Chase & Co. raised their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a report on Friday, February 9th. TheStreet upgraded Zimmer Biomet from a "c" rating to a "b-" rating in a research note on Thursday, February 8th. Royal Bank of Canada restated an "outperform" rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 9th. Finally, Evercore ISI upped their price target on Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research report on Thursday, April 4th. One analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Zimmer Biomet presently has an average rating of "Hold" and an average price target of $139.39.

Zimmer Biomet Trading Down 0.4 %

Shares of NYSE ZBH traded down $0.48 during mid-day trading on Monday, hitting $124.00. The stock had a trading volume of 1,041,803 shares, compared to its average volume of 1,481,584. The firm has a market cap of $25.48 billion, a P/E ratio of 25.46, a price-to-earnings-growth ratio of 2.29 and a beta of 1.01. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.78 and a current ratio of 1.61. The business has a 50 day moving average price of $126.73 and a two-hundred day moving average price of $118.94. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $149.25.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The medical equipment provider reported $2.20 EPS for the quarter, beating the consensus estimate of $2.15 by $0.05. The firm had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The company's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.88 earnings per share. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 annualized dividend and a yield of 0.77%. Zimmer Biomet's payout ratio is 19.63%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.